In the Media - Starpharma

Starpharma featured on Bulls N' Bears

Sep 22nd, 2023

Starpharma was featured on 3AW's Bulls N' Bears following the announcement about positive DEP® irinotecan clinical results that will be presented at international oncology conference. This was recorded on 20 September 2023. ... Read More

Starpharma featured on ShareCafe

Sep 22nd, 2023

Starpharma was featured on ShareCafe's "Hidden Gems Webinar" following the announcement about positive DEP® irinotecan clinical results that will be presented at international oncology conference. This was recorded on 22 September 2023. ... ... Read More

Starpharma interviewed for Fear and Greed podcast

Sep 22nd, 2023

Starpharma was featured in Business News' Fear and Greed following the announcement about positive DEP® irinotecan clinical results that will be presented at international oncology conference.This was recorded on 20 September 2023. ... Read More

Starpharma interviewed for ausbiz

Sep 15th, 2023

Starpharma was featured in ausbiz's Small Caps segment following the announcement about positive DEP® irinotecan clinical results that will be presented at international oncology conference.This was recorded on 14 September 2023. Read More

Commencement of CFO and Company Secretary (ASX Announcement)

Apr 3rd, 2023

Melbourne, Australia; 3 April 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce that, further to the announcement on 3 March 2023, Mr Justin Cahill commences in the role of Chief Financial Officer (CFO) and Company Secretary today.

Starpharma presents at ASX Small and Mid-Cap Conference (ASX Announcement)

Mar 22nd, 2023

Melbourne, Australia; 22 March 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) announces that Starpharma CEO Dr Jackie Fairley will present a brief overview of the Company at the ASX Small and Mid-Cap Conference today at 11:00am AEDT. The Conference showcases selected ASX-listed companies to Australian investors.

CFO and Company Secretary Appointment (ASX Announcement)

Mar 3rd, 2023

Melbourne, Australia; 3 March 2023: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Mr Justin Cahill as Chief Financial Officer (CFO) and Company Secretary, following an extensive executive search process. Justin will commence in the role in early April 2023.

Interim Report and Half-Year Financial Results - H1FY23 (ASX Announcement)

Feb 28th, 2023

Melbourne, Australia; 28 February 2023: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today releases its interim report and half-year financial results for the period ended 31 December 2022 (H1 FY23).

Dr Russell Basser appointed as non-executive director (ASX Announcement)

Jan 31st, 2023

The Board of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Russell Basser as an independent non-executive director, effective from 20 February 2023.

Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL.

Dr Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited / CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring / CSL Limited.

ADCs Built On Starpharma Delivery Tech To Be Tested By Merck

Aug 22nd, 2022

"As it works to expand its antibody-drug conjugate (ADC) capabilities, Merck has strengthened its links to Starpharma by signing a second partnership that will allow it to assess potential candidates using a dendrimer drug delivery technology", reports World Pharma Today.